lenacapavir (Sunlenca) Report issue

Small molecule Approved FDA First in Class Fast Track FDA Breakthrough Therapy FDA Priority Review FDA

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: CC(C)(C#Cc1ccc(-c2ccc(Cl)c3c(NS(C)(=O)=O)nn(CC(F)(F)F)c23)c([C@H](Cc2cc(F)cc(F)c2)NC(=O)Cn2nc(C(F)(F)F)c3c2C(F)(F)[C@@H]2C[C@H]32)n1)S(C)(=O)=O
  • InChIKey: BRYXUCLEHAUSDY-WEWMWRJBSA-N
  • Mol. Mass: 968.3
  • ALogP: 7.66
  • ChEMBL Molecules:
    lenacapavir  
    lenacapavir sodium  
More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral, Parenteral
  • Pro Drug: No

Organizations (5)

Research & Development (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (2)

Approved Indications (2)


 

HIV-1

HIV Infections (approved 2022)

Experimental Indications - Clinical Trial Phases 1-4 (1)


 

HIV Infections (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial Organizations: 5

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue